NEW YORK – Electronic health record company Omny Health and molecular diagnostics firm Scipher Medicine said Thursday that they have entered a partnership aimed at advancing precision medicine efforts for immunology.
Under the collaboration, the companies will work to integrate transcriptomic data from Scipher Medicine's PrismRA test with Omny Health's EHR network, which reaches more than 80 million patients.
Omny Health’s network already includes data from nearly 250,000 patients with rheumatoid arthritis, covering key metrics such as functional status, lab values (ESR, CRP), joint counts, CDAI, and DAS28. Scipher's PrismRA is an RNA-based assay designed to aid doctors in choosing which drugs to prescribe their patients. To date, the company has tested over 40,000 patients.
The companies are hoping that combining molecular data from Scipher's testing with Omny's existing data will support development of more targeted therapies and improve overall patient outcomes among Omny's life sciences partners.
Financial terms of the partnership were not disclosed.